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Intravenous immunoglobulin (IVIG) administration in sepsis has been surrounded with 
controversies since the publication of the first international consensus meeting on this 
potential therapy almost 40 years ago 1. Researchers called for evaluation of different 
treatment doses and durations of IVIG treatment in sepsis, when one of the earliest 
randomised controlled trials (RCTs) showed no effect and higher rate of significant 
complications in the IVIG group, using 150 mg/kg bolus dose for three consecutive days 2. 
Recent clinical trials used a wide variety of dosing regimes ranging from 200 mg/kg/day to 
1000 mg/kg/day, with similarly disappointing results 3-5. The study presented in the current 
issue of the Journal by Nakamura et al. is the first step in the right direction 6. They found 
that single administration of 15g IVIG versus 5g IVIG boluses administered over a three-day 
period resulted in similar clinical outcomes in a cohort of propensity matched sepsis 
patients from a single Japanese centre. This equates to around 200-220 mg/kg in the single 
dose and 70-80 mg/kg in the divided dose groups, although the weight of their patients is 
not reported. The dose in the Nakamura study was confined to the approved dose used in 
Japan and as the IVIG administration for the indication of sepsis is not routinely reimbursed 
in other healthcare systems, we have to commend their pragmatic approach investigating 
whether a larger single dose has similar effects to a smaller, divided dose 6. The last RCT to 
report on the use of IVIG in sepsis caused by severe community acquired pneumonia, a 
condition which also presented in half of the patients in the Nakamura study, used similar 
dose (approximately 200mg/kg/day) 4. However, the CIGMA investigators used this higher 
dose for three days and still reported no significant difference in the important clinical 
outcome measures such as ventilator-free days and mortality 4. In their exploratory analysis, 
they have shown that IVIG might confer benefit in patients with high C-reactive protein 
(CRP) and low IgM levels as well as for patients with high procalcitonin  levels, with 
significantly more patients surviving with less organ dysfunction in the IVIG group 4. It is 
important to note that in the Nakamura study, the single 15g IVIG dose has resulted in 
faster resolution of inflammatory markers, than the lower divided dose and their patients 
shared similar biochemical characteristics with the high CRP and high procalcitonin 
subgroup of the CIGMA trial 4,6. These important findings point towards the efficacy and 
potential clinical utility of higher dose IVIG. As the proposed biological effect of IVIG therapy 
in sepsis is immunomodulation, it is accepted that the highest dose tolerated with the most 
pronounced response should be used 7. The currently tested mean dose of ~200mg/kg is 
only sufficient to replace the reduced level of IVIG in the serum, whereas for 
immunomodulatory effects doses of greater than 500mg/kg for more than 2 days are 
needed 7. For instance, Tagami et al. have investigated the effect of 5g IVIG (70-80mg/kg) 
the dose for three days on the outcome of patients suffering from septic shock due to 
pneumonia in a propensity matched analysis 8. They found no beneficial effect on the rate 
of ventilator-of shock-free days and 28-day mortality. Based on the data reported in these 
earlier studies, a Phase II dose finding trial can safely discount the use of 5g/day or 70-
80mg/kg regime, which otherwise could be seen as an important potential comparator 
based on current clinical practice.  
It appears from the recent publications of the different Japanese groups that they have an 
opportunity to combine forces and use the national database for IVIG administration to 
further explore the questions of dose and patient stratification 3,8,9.   
Stratification of patients to groups which might have benefit from an experimental therapy 
have been advocated for more than a decade, with little effect on trial design to date. 
Recent discoveries from the group of Shankar-hari et al. help us to understand the biological 
processes of immunoglobulin deficiency and also point towards better diagnostic tools for 
stratification of critically ill patients with sepsis 9. They demonstrated, that increased light 
chain levels with low immunoglobulin levels suggest impaired immunoglobulin assembly 10. 
These low immunoglobulin levels could also be a consequence of changes in the relative 
proportions of B-cell subsets. B-cell apoptosis appears to be greater in memory cells when 
compared with naive B cells. This suggests that B-cell depletion is not a consequence of 
impaired bone marrow production 11. Similarly to the CIGMA investigators and others, we 
have also found that the combined presence of low levels of the endogenous 
immunoglobulins IgG1, IgM and IgA in plasma is associated with reduced survival in patients 
with sepsis and multi-organ failure and the low IgM levels correlated with the high CRP 
values (courtesy of Dr Heurich-Sevchenko, unpublished data) 4,12. It is plausible, that to 
achieve maximum effect of immunomodulation, targeting certain subgroups of sepsis 
patients, such as those at highest risk of pro-inflammatory overdrive and impaired 
immunoglobulin homeostasis, could benefit more from the higher doses of IVIG 
replacement.  
Historically, IVIGs were used to target Gram-positive infections, especially infections caused 
by Streptococcus and Staphylococcus species 1. New markers, such as soluble-TLR2 levels, 
which appear to be increasing in response to Gram-positive bacterial insult, could highlight 
those patients who are at highest risk of developing the dysregulated response to severe 
infection 13. Combined with more conventional infectious markers, such as CRP and PCT, it 
could be used for identifying subpopulations (such as patients with exaggerated 
inflammation) who benefit the most in future trials.  
The international critical care community has spent 40 years on exploring a biologically 
plausible treatment option for severe infection, with countless failed multicentre trials, 
whilst failing to acknowledge and address the lack of fundamental knowledge of 
immunoglobulin homeostasis. Reading carefully the detailed information and placing one 
jigsaw on the table at a time, the smaller studies such as Nakamura et al. presented, can 
help us to design better, less harmful and more cost-effective dose finding Phase II studies 
to evaluate the effect of IVIG treatment in sepsis. 
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